Émile Lemoine

Émile Lemoine

Auto-generated profile, based on publicly available information

Émile Lemoine

Department of Neuroscience, Université de Montréal

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
DDDamon DePaoli
Damon DePaoli
ÉLÉmile Lemoine
Émile Lemoine
KEKatherine Ember
Katherine Ember
MPMartin Parent
Martin Parent
MPMichel Prud’hOmme
Michel Prud’hOmme
DCDaniel C. Côté
Daniel C. Côté
Neurosurgery can be used to treat a multitude of disorders ranging from brain tumors and cancers to traumatic brain injury, epilepsy, and Parkinson’s disease (PD). 13.8 million neurosurgical procedures are carried out worldwide every year, and it is estimated that an additional 5 million neurosurgical conditions go untreated annually.1 Neurosurgeons face many challenges that are unmet by modern surgical techniques: incomplete tumor resection, inaccurate surgical guidance, expensive and inefficient intraoperative diagnostics, and a relatively high risk of adverse events.

12 January 2019 in Journal of Biophotonics
Verified
Journal Article
Closed access
PDF file
JDJoannie Desroches
Joannie Desroches
ÉLÉmile Lemoine
Émile Lemoine
MPMichael Pinto
Michael Pinto
EMEric Marple
Eric Marple
KUKirk Urmey
Kirk Urmey
FLFrédéric Leblond
Frédéric Leblond

15 October 2019 in The Analyst
Verified
Journal Article
Closed access
PDF file
ÉLÉmile Lemoine
Émile Lemoine
FDFrédérick Dallaire
Frédérick Dallaire
RYRajeev Yadav
Rajeev Yadav
RARajeev Agarwal
Rajeev Agarwal
SKSamuel Kadoury
Samuel Kadoury
FLFrédéric Leblond
Frédéric Leblond
Raman spectroscopy is a promising tool for neurosurgical guidance and cancer research. Quantitative analysis of the Raman signal from living tissues is, however, limited. Their molecular composition is convoluted and influenced by clinical factors, and access to data is limited. To ensure acceptance of this technology by clinicians and cancer scientists, we need to adapt the analytical methods to more closely model the Raman-generating process. Our objective is to use feature engineering to develop a new representation for spectral data specifically tailored for brain diagnosis that improves interpretability of the Raman signal while retaining enough information to accurately predict tissue content. The method consists of band fitting of Raman bands which consistently appear in the brain Raman literature, and the generation of new features representing the pairwise interaction between bands and the interaction between bands and patient age. Our technique was applied to a dataset of 547 in situ Raman spectra from 65 patients undergoing glioma resection. It showed superior predictive capacities to a principal component analysis dimensionality reduction. After analysis through a Bayesian framework, we were able to identify the oncogenic processes that characterize glioma: increased nucleic acid content, overexpression of type IV collagen and shift in the primary metabolic engine. Our results demonstrate how this mathematical transformation of the Raman signal allows the first biological, statistically robust analysis of in vivo Raman spectra from brain tissue.

21 April 2020 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
FDFrédérick Dallaire
Frédérick Dallaire
FPFabien Picot
Fabien Picot
JTJean-Philippe Tremblay
Jean-Philippe Tremblay
GSGuillaume Sheehy
Guillaume Sheehy
ÉLÉmile Lemoine
Émile Lemoine
FLFrédéric Leblond
Frédéric Leblond
<!-- *** Custom HTML *** --> Significance: Ensuring spectral quality is prerequisite to Raman spectroscopy applied to surgery. This is because the inclusion of poor-quality spectra in the training phase of Raman-based pathology detection models can compromise prediction robustness and generalizability to new data. Currently, there exists no quantitative spectral quality assessment technique that can be used to either reject low-quality data points in existing Raman datasets based on spectral morphology or, perhaps more importantly, to optimize the in vivo data acquisition process to ensure minimal spectral quality standards are met. Aim: To develop a quantitative method evaluating Raman signal quality based on the variance associated with stochastic noise in important tissue bands, including C─C stretch, CH2 / CH3 deformation, and the amide bands. Approach: A single-point hand-held Raman spectroscopy probe system was used to acquire 315 spectra from 44 brain cancer patients. All measurements were classified as either high or low quality based on visual assessment (qualitative) and using a quantitative quality factor (QF) metric. Receiver-operator-characteristic (ROC) analyses were performed to evaluate the performance of the quantitative metric to assess spectral quality and improve cancer detection accuracy. Results: The method can separate high- and low-quality spectra with a sensitivity of 89% and a specificity of 90% which is shown to increase cancer detection sensitivity and specificity by up to 20% and 12%, respectively. Conclusions: The QF threshold is effective in stratifying spectra in terms of spectral quality and the observed false negatives and false positives can be linked to limitations of qualitative spectral quality assessment. There is growing interest in medicine for systems and methods integrating Raman spectroscopy into clinical workflows to enhance the molecular informational content provided to clinicians.1 In particular, over the last decade, there has been significant efforts developing Raman microspectroscopy to complement standard histopathology analyses to improve diagnostic accuracy (e.g., reduce interpathologists variance) and create new avenues to improve disease stratification by providing patient-specific therapeutic options.2,3 Intraoperative point-probe Raman spectroscopy systems have also been developed lending rapid tissue characterization and classification to guide surgical procedures based on statistical models produced using machine learning techniques.4 For example, instruments have been developed to help reduce instances of positive margins in breast-conserving surgery,5 to detect normal brain invaded with cancer cells during glioma surgery,6,7 and to characterize prostate tissue;8 they have been integrated in endoscopic procedures to characterize suspicious lesion in the gastrointestinal tract.9 The biochemical information conveyed by a Raman measurement consists of a detailed spectral tissue fingerprint conveying information relating to Raman-active vibrational modes (e.g., C─C stretch, CH2/CH3 deformations, and vC═C) associated with native biomolecules. The relative contribution of those bonds to a spectrum can be reinterpreted as a relative fraction of lipids (e.g., phospholipids and cholesterol), nucleic acids, proteins (e.g., collagen and porphyrins), and amino acids (e.g., thymine and phenylalanine). Beyond molecular sensitivity, the strengths of Raman spectroscopy include the fact that it does not require the injection of a tracer and that it can be nondestructive and nonionizing, usually interrogating tissue with excitation light in the near-infrared10 at low power levels. However, an important limitation of Raman spectroscopy is that the fraction of the signal directly attributable to molecular vibrational information can be several orders of magnitude smaller when compared to background signals (Fig. 1). Background contributions are usually mostly attributable to intrinsic tissue fluorescence although other sources of background associated with instrument response (e.g., fluorescence or Raman signal generated from silica in optical fibers) or bleed-through at laser excitation can negatively impact Raman signal detection. <!-- named anchor --> Fig. 1 (a) Depiction of the relative proportion of different sources of signal in a human brain measurement made using a Raman spectroscopy system, including dark counts and background (e.g., fluorescence from tissue and optical components). Measurements are shown that were averaged over different number of repeated acquisitions: n=5, 20, and 50. The 1441  cm−1 band is highlighted to represent a band typically used to assess spectral quality. For visualization purposes, the Raman signal shown is amplified by a factor of 50. (b) Processed Raman spectra acquired in vivo in brain cancer tissue for different numbers of repeat measurements (1, 10, and 50). (c) QF as a function of the number of repeat measurements. In both (b) and (c), the solid line and shaded area represent the average and the standard deviation over 15 spectra acquired at different brain locations, respectively. An outstanding issue in tissue Raman spectroscopy is that there is no universal approach allowing to quantitatively and automatically establish the spectral quality associated with a Raman measurement. This introduces ambiguities in signal interpretation with no guarantee that the vibrational information is captured at sufficiently high levels of inelastic scattering photon counts for pathology detection. In most experiments reported in the literature, qualitative data quality assessment is made offline based on visual evaluation of the spectra rather than using unbiased quantitative criteria. In fact, it is common to simply assess the presence of relevant tissue Raman bands, including phenylalanine at 1004  cm−1, phospholipids at 1087  cm−1, tryptophan at 1339  cm−1, lipid side chains–amino acids at 1441  cm−1, and collagen–nucleic acids at 1659  cm−1. However, a quantitative method was developed to filter undesirable skin measurements using principal component analysis to detect and remove outliers in a dataset;11 however, this approach is agnostic to the actual biomolecular tissue content. In biomedical tissue optics applications of Raman spectroscopy reported in the literature, qualitative spectral quality is optimized by tuning the imaging parameters (laser power at the sample, detector exposure time, and number of repeat measurements) all the while ensuring tissue absorption-related heat generation remains sufficiently low not to cause tissue damage. This is especially important for instruments intended to be used in a clinical environment where attaining optimal inelastic scattering photon counts is critical if measurements are to be used to detect subtle changes associated with pathological tissue alterations. Finding standardized and quantitative manners to assess spectral quality is a complex problem not only because of the observed variability in the relative strength of different Raman bonds across tissue types, but also because biological tissue can be highly heterogeneous in terms of intrinsic fluorescence, absorption (tissue chromophores, e.g., hemoglobin, and pigments, e.g., melanin), and elastic scattering (organelles, cell nuclei, and membranes). As an example, consider measurements made at two different tissue locations having the same concentration of Raman-active biomolecules, but with different levels of background. Then, using identical imaging parameters with the same system at both locations would result in detected Raman photon counts with different stochastic variances from shot noise, potentially resulting in one of the measurements being unable to capture subtle yet important biological Raman peaks (e.g., phenylalanine). These signal quality variations could compromise classification model robustness and performance. We are presenting the development and in-human validation of a technique that can be used to automatically and unambiguously quantify the shot noise specifically related to the Raman contribution of a spectroscopic measurement, which is the sum of photons from background signals and inelastically scattered Raman photons. The method is applied to in vivo human brain data to demonstrate that the resulting Raman signal-to-noise ratio (SNR) can be quantified and used as a surrogate for spectral quality either retrospectively on existing datasets or live during surgical procedures. The new quality metric could be used to establish quantitative thresholds ensuring spectral quality of intraoperative measurements through live automated adjustment of imaging parameters. This could be used to ensure interpatients homogeneity of Raman spectral quality in the scope of clinical studies and trials. It is well-known that the noise affecting optical measurements made with light sensors [e.g., charged-coupled devices (CCD)] includes at least three important contributions: thermal noise, readout noise, and shot noise (photon noise). For CCD-based detection, thermal noise originates from thermo-generated charges in the depletion region of the chip and readout noise is associated with the measurement of these charges by the readout device. Contrary to those electronic sources of stochastic noise, shot noise is a direct consequence of the particulate nature of light and is common to any photon-detection device. In Raman spectroscopy of biological tissue, thermal and readout noise are usually negligible compared to shot noise because of the large measurement backgrounds. Shot noise follows a Poisson distribution, but in Raman spectroscopy, it can be approximated as a Gaussian distribution because the overall “fluorescence + Raman” detected light intensity I is always large. This is because significant numbers of Raman photons (relative to the background) can only result if large fluorescence counts are reached. Then, the formula for overall SNR is I/I (intensity over variance), where I can be modeled as a sum over all detected light contributions, namely background (fluorescence, instrument response, and laser bleed-through), dark counts, and Raman signal. The SNR associated with a measurement can be expressed as the sum of the SNR values associated with each of these individual sources. As a result, the formula quantifying only the Raman SNR—i.e., the shot noise associated only with the Raman component of the signal—within a spectral bin is given by <!-- named anchor --> Eq. (1)Raman SNRj≈ntISrjrj+aj,where j=1 to N is an index labeling the individual spectral bins and N is the number of bins of which a spectrum is composed, usually around 1000 for most spectrometers. Other physical quantities in the formula are the background intensity ai, the Raman contribution ri, the number of repeat measurements n at each location, the acquisition time t, and the laser power at the sample IS.The hypothesis tested here is that a quality factor (QF) metric can be computed based on the Raman SNR formula and used to quantitatively assess the spectral quality of individual tissue Raman spectra. This will be achieved using an in vivo brain dataset acquired using a single-point hand-held Raman spectroscopy probe system published elsewhere.12 The dataset consists of 315 in situ spectra from 44 brain cancer patients. On average, 7 acquisition points were selected for each patient and n=5 to 10 co-located spectra acquired at each point. The laser power Is (at sample) ranged from 10 to 75 mW and the exposure time was either 50 or 75 ms; both laser power and integration time were recorded to be used in Eq. (2). For each acquisition point, a co-located biopsy sample was analyzed by an expert neuropathologist and assigned one of three labels: normal, cancer, or infiltrated tissue (normal tissue with low density of cancer cells). The ratio of cancer-to-normal samples in the dataset was approximately 1:1.75. To provide a ground truth in terms of signal quality, all spectra were qualitatively evaluated based on their quality (i.e., presence and relative intensity of standard inelastic scattering peaks expected in tissue) by three independent reviewers (F.D., G.S., and E.L.) using the LabelBox platform (San Francisco, California). Before being presented to each of the reviewers, the spectra were randomly shuffled and their assigned pathology label hidden. Each spectrum was graded on a 1 to 3 scale (higher values corresponding to higher quality) and the sum of all reviewer scores corresponds to the final quality score (qS).12 Specific criteria were used such as visual assessment of ubiquitous Raman tissue peaks, including phenylalanine at 1004  cm−1, a nucleic acid band at 1082  cm−1, the amide III band at 1300  cm−1, the CH2/CH3 deformation band at 1441  cm−1, and the amide I band at 1659  cm−1. In another experiment, 15 in vivo brain measurements were made during surgery in one glioblastoma patient to evaluate the impact of n (number or repeat measurements) on the Raman SNR. For this experiment, measurements were made only within an area associated with tumor tissue with a laser power of 30 mW (at sample), an integration time varying between 90 and 600 ms, and n=50. The integration time was automatically determined through an automatic exposure control code automatically adjusting time to ensure at least 50% of the CCD dynamical range was used for each measurement. The quantitative spectral QF is defined as <!-- named anchor --> Eq. (2)QF=∑j=1kRaman SNRj,where the sum runs over all spectral bins within the Raman bands selected to assess quality (Table 1); for example, see Fig. 1 where the 1441  cm−1 band is highlighted. To compute the QF metric, raw spectroscopic data within the in vivo brain datasets were preprocessed to separate the Raman contributions ri from the background ai within each spectral bin. Data preprocessing steps detailed elsewhere12 included: (1) dark noise...

4 August 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ÉLÉmile Lemoine
Émile Lemoine
DTDenahin Toffa
Denahin Toffa
GDGeneviève Pelletier-Mc Duff
Geneviève Pelletier-Mc Duff
AXAn Qi Xu
An Qi Xu
MJMezen Jemel
Mezen Jemel
EAElie Bou Assi
Elie Bou Assi
Predicting seizure recurrence risk is critical to the diagnosis and management of epilepsy. Routine electroencephalography (EEG) is a cornerstone of the estimation of seizure recurrence risk. However, EEG interpretation relies on the visual identification of interictal epileptiform discharges (IEDs) by neurologists, with limited sensitivity. Automated processing of EEG could increase its diagnostic yield and accessibility. The main objective was to develop a prediction model based on automated EEG processing to predict one-year seizure recurrence in patients undergoing routine EEG. We retrospectively selected a consecutive cohort of 517 patients undergoing routine EEG at our institution (training set) and a separate, temporally shifted cohort of 261 patients (testing set). We developed an automated processing pipeline to extract linear and non-linear features from the EEGs. We trained machine learning algorithms on multichannel EEG segments to predict one-year seizure recurrence. We evaluated the impact of IEDs and clinical confounders on performances and validated the performances on the testing set. The receiver operating characteristic area-under-the-curve for seizure recurrence after EEG in the testing set was 0.63 (95% CI 0.55–0.71). Predictions were still significantly above chance in EEGs with no IEDs. Our findings suggest that there are changes other than IEDs in the EEG signal embodying seizure propensity.

21 December 2023 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
ÉLÉmile Lemoine
Émile Lemoine
JBJoel Neves Briard
Joel Neves Briard
BRBastien Rioux
Bastien Rioux
OGOumayma Gharbi
Oumayma Gharbi
RPRenata Podbielski
Renata Podbielski
EAElie Bou Assi
Elie Bou Assi
Background: Computational analysis of routine electroencephalogram (rEEG) could improve the accuracy of epilepsy diagnosis. We aim to systematically assess the diagnostic performances of computed biomarkers for epilepsy in individuals undergoing rEEG. Methods: We searched MEDLINE, EMBASE, EBM reviews, IEEE Explore and the grey literature for studies published between January 1961 and December 2022. We included studies reporting a computational method to diagnose epilepsy based on rEEG without relying on the identification of interictal epileptiform discharges or seizures. Diagnosis of epilepsy as per a treating physician was the reference standard. We assessed the risk of bias using an adapted QUADAS-2 tool. Results: We screened 10 166 studies, and 37 were included. The sample size ranged from 8 to 192 (mean=54). The computed biomarkers were based on linear (43%), non-linear (27%), connectivity (38%), and convolutional neural networks (10%) models. The risk of bias was high or unclear in all studies, more commonly from spectrum effect and data leakage. Diagnostic accuracy ranged between 64% and 100%. We observed high methodological heterogeneity, preventing pooling of accuracy measures. Conclusion: The current literature provides insufficient evidence to reliably assess the diagnostic yield of computational analysis of rEEG. Significance: We provide guidelines regarding patient selection, reference standard, algorithms, and performance validation.